Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK1 | Q15118 | 4/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.36 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 2/20 | 0.32 |
| ▸ | CA1 | P00915 | 2/20 | 0.32 |
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
| ▸ | CA9 | Q16790 | 2/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.32 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28185123 | 0.84 | POLB (0.40) | PDK1POLBPDK2PDK3CA12 | |
| SCHEMBL17893278 | 0.82 | PDK1 (0.42) | PDK1POLBPDK2PDK3DPP4 | |
| SCHEMBL554535 | 0.80 | USP2 (0.43) | PDK1PDK2PDK3 | |
| SCHEMBL554773 | 0.80 | USP2 (0.43) | PDK1PDK2PDK3 | |
| SCHEMBL554536 | 0.80 | USP2 (0.43) | PDK1PDK2PDK3 | |
| SCHEMBL16797367 | 0.78 | PDK1 (0.41) | PDK1PDK2PDK3DPP4CA12 | |
| SCHEMBL18497425 | 0.78 | HRH3 (0.37) | HRH3 | |
| SCHEMBL18497648 | 0.78 | HRH3 (0.37) | HRH3 | |
| SCHEMBL18497423 | 0.78 | HRH3 (0.37) | HRH3 | |
| SCHEMBL5560259 | 0.76 | PDK1 (0.59) | PDK1POLBPDK2PDK3DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3334728-A1 | FUMAGILLOL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | Zafgen, Inc. (US) | 2018-06-20 | — | — | EP | claimed |
| WO-2017027684-A1 | FUMAGILLOL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN, INC. (US) | 2017-02-16 | — | — | WO | claimed |
| US-20190084968-A1 | FUMAGILLOL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN INC (US) | 2019-03-21 | — | — | US | disclosed |
| US-20190084969-A1 | FUMAGILLOL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN INC (US) | 2019-03-21 | — | — | US | disclosed |
| US-10023561-B2 | Fumagillol heterocyclic compounds and methods of making and using same | ZAFGEN, INC. (US) | 2018-07-17 | — | — | US | disclosed |
| EP-3334728-A1 | FUMAGILLOL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | Zafgen, Inc. (US) | 2018-06-20 | — | — | EP | disclosed |
| CN-105367482-B | N acyl sulfonamides apoptosis accelerator | 阿斯利康(瑞典)有限公司 | 2017-12-12 | — | — | CN | disclosed |
| US-20170342058-A1 | FUMAGILLOL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN, INC. | 2017-11-30 | — | — | US | disclosed |
| US-9682965-B2 | Fumagillol heterocyclic compounds and methods of making and using same | ZAFGEN, INC. (US) | 2017-06-20 | — | — | US | disclosed |
| US-20170066749-A1 | FUMAGILLOL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN, INC. | 2017-03-09 | — | — | US | disclosed |
| WO-2017027684-A1 | FUMAGILLOL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN, INC. (US) | 2017-02-16 | — | — | WO | disclosed |
| EP-2601177-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | AstraZeneca AB (SE) | 2013-06-12 | — | — | EP | disclosed |
| WO-2012017251-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ASTRAZENECA AB (SE) | 2012-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190084969-A1 | FUMAGILLOL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | METAP2, FAP, FOLH1 | PDK1 1377/4885POLB 1642/4885PDK2 894/4885 |
| US-20170066749-A1 | FUMAGILLOL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | METAP2, FAP, FOLH1 | PDK1 1377/4885POLB 1642/4885PDK2 894/4885 |
| US-20170342058-A1 | FUMAGILLOL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | METAP2, FAP, FOLH1 | PDK1 1377/4885POLB 1642/4885PDK2 894/4885 |
| US-20190084968-A1 | FUMAGILLOL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | METAP2, FAP, FOLH1 | PDK1 1377/4885POLB 1642/4885PDK2 894/4885 |
| US-10023561-B2 | Fumagillol heterocyclic compounds and methods of making and using same | METAP2, FAP, FOLH1 | PDK1 1377/4885POLB 1642/4885PDK2 894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.